Ani Pharmaceuticals Inc (ANIP) - News Archive

ANI Pharmaceuticals Receives FDA Approval for Purified Cortrophin Gel Prefilled Syringe Amidst Strong Revenue GrowthIn a significant stride within the biopharmaceutical landscape, ANI Pharmaceuticals, Inc. (NASDAQ: ANIP...

ANI Pharmaceuticals Unveils Nitazoxanide Tablets Amid Mixed Market Performance On March 19, 2025, ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), a prominent player in the pharmaceutical industry, announced the launch of Nita...

In a significant financial maneuver poised to bolster its growth trajectory, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) recently announced the successful completion of a buyout of its 3.125% perpetual royalty obligation t...

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has announced the successful launch of its generic Prucalopride Tablets, following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Ap...

ANI Pharmaceuticals, Inc. has announced the successful launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, a novel therapeutic solution designed for symptom management in respiratory ai...

In an industry where strategic partnerships can signify critical growth trajectories, ANI Pharmaceuticals Inc. (NASDAQ: ANIP) and Alimera Sciences have recently scheduled the closing of their merger for September 16, 20...

On September 10, 2024, ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced an update regarding the acquisition of Alimera Sciences, Inc. (NASDAQ: ALIM), a significant move that could alter the landscape for the company a...

ANI Pharmaceuticals, Inc. Successfully Closes $316.25 Million Offering of Convertible Senior Notes, Demonstrating Investor Confidence in the Companyns Growth PotentialIn a significant development for ANI Pharmaceuticals...

ANI Pharmaceuticals, Inc. has recently announced the pricing of an upsized $275.0 million aggregate principal amount of convertible senior notes due 2029. The private offering to qualified institutional buyers was made...

Princeton, N.J., Aug. 07, 2024 - ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) has recently announced its plans to offer $250,000,000 aggregate principal amount of convertible senior notes due 2029 (the...

ANI Pharmaceuticals Introduces L-Glutamine Oral Powder, Expanding its Generic Drug Portfolio while Achieving Impressive Revenue GrowthIn a recent breakthrough, ANI Pharmaceuticals, Inc. (ANI or the Company) has confirme...

ANI Pharmaceuticals Continues Strong Market Presence with FDA Approval and Launch of New Generic Medications Princeton, N.J., July 02, 2024 - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), a leading U.S. specialty pharmaceut...

ANI Pharmaceuticals Inc. (NASDAQ: ANIP) is a pharmaceutical company that focuses on the development, manufacturing, and distribution of generic pharmaceutical products. With a market capitalization of $1102 million, ANI...

ANI Pharmaceuticals Announces the Launch of Kionex Suspension BAUDETTE, Minn., May 20, 2024 ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfona...

The launch of Baclofen Oral Suspension marks a momentous milestone for ANI Pharmaceuticals. This generic version of Fleqsuvy offers patients an affordable yet equally effective treatment option for muscle spasms and mul...

ANI Pharmaceuticals, a leading pharmaceutical company, has recently made a significant announcement regarding the launch of Levofloxacin Oral Solution, a generic version of the widely-used Reference Listed Drug (RLD), L...

ANI Pharmaceuticals, a leading pharmaceutical company, has made yet another groundbreaking achievement with the successful launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. This remarkable development n...